Treatment for rectal cancer patients is constantly evolving towards a highly tailored approach. An updated and multidisciplinary team of specialists should work together in order to achieve this. The goal is to offer the best treatment with the lowest toxicity rate.

In this lecture, Robert Glynne-Jones from the Barnet Hospital talks about several issues regarding preoperative QRD for patients with clinical stage II/III rectal cancer.

Among other things, he explains the importance of standardization regarding:

Short course vs long course therapy
Patients selection criteria
International Guidelines

Faculty keyboard_arrow_down

Dr. Robert Glynne Jones Consultant Clinical Oncologist, Macmillan Lead Clinician in Gastrointestinal and Colorectal Cancer, Mount Vernon Hospital, Watford and Barnet General Hospitals; Chief Medical Advisor, National UK Charity Bowel Cancer UK, UK Surgical Oncology